cyrilzakka/clinical-trials huggingface dataset:
Age-Related Changes in Sleep-Dependent Emotional Memory

Memory influences emotional well being. Research has shown that having a negative emotional bias contributes to both emotion dysregulation and depression. Conversely, reactivating positive memories has been shown to reduce stress and symptoms of depression. In young adults, sleep is widely implicated in emotional processing, including consolidation of emotional memories. Evidence suggests that aging is associated with changes in emotion, including a positive memory bias and enhanced emotional well-being. These changes have been termed the "age-related positivity effect." However, the influence of sleep on these measures has not been investigated in healthy older individuals. The objective of this research is to understand the role of sleep in emotional memory consolidation and emotional well-being across adulthood. We hypothesize that sleep contributes to the age-related positivity effect in memory and affect. Our alternative hypothesis is that age-related decreases in sleep are responsible for reduced emotional memory processing over healthy aging.


Eligibility Criteria:
Inclusion Criteria:

* 18-30 or 50-80 years of age
* Have no history of a sleep disorder
* Have no history of neurological disease or injury
* Have no history of psychiatric illness (anxiety or mood disorder, schizophrenia, etc.)
* No history of chemotherapy
* Not be taking medications which effect sleep
* Habitually sleep more than 6 or more hours per night
* Be able to walk freely and independently
* Have normal to corrected-to-normal vision
Effectiveness of Influenza Vaccine Reminder Systems

Influenza disease causes significant morbidity and mortality in the Unites States each year. Although influenza can cause morbidity in otherwise healthy individuals, adults with chronic lung disease have significantly increased rates of hospitalization from influenza-related illnesses compared to healthy adults. Influenza vaccination is the primary means of preventing influenza disease. Annual influenza vaccination is recommended for all individuals 6 months of age and older in the United States. Influenza vaccination rates are sub-optimal, however. Patient reminder/recall has been shown, in multiple studies across a variety of age groups and health conditions, to increase immunization rates. However, the effectiveness and cost-effectiveness of different types of reminder/recall has not been well-studied, particularly in adults. In the fall of 2012, the Population and Prevention Services (PPS) Department at Kaiser Permanente Colorado (KPCO) is using 3 different reminder strategies for influenza vaccination among adults with asthma and chronic obstructive pulmonary disease (COPD). The objective of this study is to provide a rigorous evaluation of which strategy is more effective and more cost-effective, to promote influenza vaccination.

At KPCO, postcards are typically sent to members each fall, to remind members to receive their annual influenza vaccine. At KPCO, interactive voice response (IVR) systems have been utilized for a number of prevention reminders, but have not in the past been used for influenza vaccination reminders. For the 2012-2013 influenza season, the PPS department is going to send three different types of reminders to their adult patients with certain chronic lung diseases (specifically, adults with asthma and COPD): postcards only; IVR reminders only; postcards plus IVR reminders. This study seeks to evaluate the effectiveness, and cost-effectiveness, of an already-finalized operational plan for influenza reminders.

Eligibility Criteria:
Inclusion Criteria:

* Age 19 to 64 years
* Enrolled in Kaiser Permanente Colorado health plan
* Diagnosis of asthma and/or chronic obstructive pulmonary disease

Exclusion Criteria:

* Subjects living in households with other individuals in high-risk categories for influenza morbidity
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).


Eligibility Criteria:
Inclusion Criteria:

* Signed written informed consent
* Patients with macular edema due to RVO (confirmed by fundus photography, fluorescein angiography, OCT)
* Male and female aged from 18 to 70
* Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/400 to 20/30 using ETDRS chart

Exclusion Criteria:

* Additional eye disease that could compromise VA
* Ocular inflammation
* Intraocular surgery ≤ 1 month before day 0
* Uncontrolled glaucoma
* Prior treatments with laser photocoagulation or other intervention for macular edema due to BRVO
* Patients aged under 18 or over 71
* Female patient in pregnancy or breast feeding
* Not suitable to regular follow up
Combined Effects Of Autogenic Drainage and Segmental Breathing Techniques in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is one of the most common life threatening disease affecting population. It is a preventable and treatable lung disease. People with COPD must work harder to breathe, which can lead to shortness of breath and/or feeling tired. Autogenic drainage (AD) works by adapting your breathing and maximizing airflow within the airways to improve ventilation and clear sputum. Segmental breathing, also referred to as localized expansion breathing, is the exercise used to improve ventilation and oxygenation. This research of randomized controlled trial will check the combined effects of segmental breathing technique and autogenic drainage technique in chronic obstructive pulmonary disease by taking sample of 40 patients through non probability convenient sampling and randomly allocating them into two groups A and B out of which A will receive both autogenic drainage and segmental breathing technique, B will receive autogenic drainage only for upto the duration of 3 days per week(20-45 min) for upto 4 weeks.Pre and post training outcomes will be measured through pulse oximeter,spirometer and BCSS.The data will be analyzed through SPSS 25.


Eligibility Criteria:
Inclusion Criteria:

* Age between 40 - 60 years.
* Diagnosed moderate COPD patients according to GOLD criteria.
* FEV / FVC ratio \< 70 years
* Stable patients can understand written and oral english,urdu trial information.

Exclusion Criteria:

* Pregnancy, due to the Pressure on pelvic and Abdomen muscles.
* Malignant disease
* Severe (RA)
* Diagnosis of Asthma and major diseases, functionally limiting diseases, life expectancy \< 3 months.
* Neurological disorders
Thoracolumbal Interfascial Plane Block Versus Erector Spinae Plane Block for Lumbar Posterior Decompression Stabilization

This study aimed to found out The Comparison Of Perioperative Analgesia Effectiveness Between Thoracolumbal Interfascial Plane Block with Erector Spinae Plane Block In Lumbar Posterior Decompression and Stabilization.

This is a double blind randomized controlled trial. Forty subject will be recruited with non-probability consecutive sampling method. Subjects who meet all inclusion criteria and do not have exclusion criteria will be asked to sign the informed consent form before included in this study. Subjects will be randomized into two groups. The first group is the group who will get Bilateral Thoracolumbal Interfascial Plane Block after general anesthesia and the second group will be the group who will get Bilateral Erector Spinae Plane Block after general anesthesia. After surgery, pain scale, time to first morphine dose, total morphine consumption in 24 hours, cardiovascular stability and adverse events will be recorded for both group.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 - 65 years old
2. Patients schedule for elective posterior decompression and stabilization lumbar spine surgery
3. ASA I - III
4. Decompression and posterior stabilization's patients who didn't caused by infection or abscess

Exclusion Criteria:

1. Patients who refuse to participate in this study
2. Body Mass Index \< 18,5 kg/m2 and \> 27,0 kg/m2
3. Patient with history of chronic opioid
4. Patient with coagulation disorder
5. Patient with cognitive disorders
6. Infection at the injection area
Minimally Invasive Surgery of the Gastro-esophageal Junction

This study will assess short and long term outcomes of individuals undergoing minimally invasive surgery of the gastro-esophageal junction (MISGEJ). Patients will respond to questionnaires on an annual basis evaluating quality of life and functionality following MISGEJ. Hospital charts will also be reviewed on an annual basis to assess patient health outcomes.


Eligibility Criteria:
Inclusion Criteria:

* All patients at the Ottawa Hospital undergoing minimally invasive surgery of the GEJ

Exclusion Criteria:

* Less than 18 years of age.
Effect of PreforPro® on Urinary and Vaginal Health

This study will investigate the effects of PreforPro® (prebiotic and bacteriophages (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae, greater \> 6.7 X 107 PFU/gram) on bacterial vaginosis.

This is a double-blinded, placebo controlled study. Each study participant will be in the study for 90 days. During the first 28 days the participants will not take study product, and will collect samples for the study in order to act as their own controls. On day 29, participants will be randomized to intervention with either PreforPro® or placebo, which they will take once daily for the remaining 62 days. There will be a total of 5 study visits during which samples will be collected, a Quality of Life questionnaire will be completed at baseline and end of study visit.

Samples for the study are: vaginal swab, faecal sample, urine sample.

Eligibility Criteria:
Inclusion Criteria:

* Female
* 18-45 years old premenopausal (period within 6 months)
* Nugent score of 4-6 (intermediate) or 7-10 (BV)
* Have an ability to collect a clean urine sample
* Prescription and over the counter medication unchanged for \> 30 days prior to the study. -Participants who are taking medications as needed (PRN) may be included if they began PRN usage \>30 days prior to baseline
* Sexually active status of the participants can be either active or inactive
* Participants must agree to use a medically approved method of birth control (e.g. hormonal contraceptives, intrauterine devices, vasectomy/tubal ligation, barrier methods and double-barrier method) and must have negative pregnancy test results at screening and baseline

Exclusion Criteria:

* Faecal incontinence
* History of urinary fistula, bladder or kidney stones, interstitial cystitis, or cystoscopic abnormalities that could be malignant
* Neurogenic bladder
* A history of currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy
* Antibiotic and/or anti-fungal medication used within the last four weeks
* Oral probiotic supplement use within 2 weeks prior the study excluding yogurt
* Drug abuse
* Uncontrolled psychological disorders
Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias

This project aims to study on one hand the early mitochondrial alterations, common or specific, occurring in peripheral cells of patients with Alzheimer's disease or related dementia and, on the other hand, identify the metabolomic biomarkers that may be at the origin of mitochondrial disturbances associated with the disease. This will be the first study combining functional analyses of mitochondria and exploratory metabolomic assessments in the same cohort at early stages of the disease.

Study will be proposed to the patient of the Nice Memory center who had a lumbar puncture and who agreed on the storage of a sample of their cerebrospinal fluid.

Two groups of patients will be compared: the Alzheimer"s disease patient with positive amyloid on the cerebrospinal fluid and the non Alzheimer patient with negative amyloid on the cerebrospinal fluid.

Blood samples will be collected at inclusion and one year to obtain the mitochondrial metabolomic signature

Eligibility Criteria:
Inclusion Criteria:

* Neurocognitive disorder with spontaneous complaint or reported for at least 6 months
* Diagnostic process according to current Haute Autorité de Santé (HAS) recommendations.
* cerebrospinal fluid biomarker dosage done within the study center and agreement to bio-collection of residual cerebrospinal fluid
* Patient having agreed to sign the informed consent
* Patient affiliated or beneficiary of a social security scheme

For alzheimer group : diagnosis of Alzheimer's disease according to NIA-AA 2024 criteria (presence of a pathogenic amyloid process in the cerebrospinal fluid)

For non alzheimer group : diagnosis of mild or major neurocognitive disorder according to Manuel diagnostique et statistique des troubles mentaux edition 5 (DSM-V) criteria, not linked to Alzheimer's disease (absence of pathogenic amyloid process in the cerebrospinal fluid)

Exclusion Criteria:

- Vulnerable people
Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution

The authors would like to investigate the blocking characteristics, surgical quality and side effects of intrathecal levobupivacaine whether there are any differences between the hyperbaric and the isobaric formulation for gynaecologic surgeries which need higher block level than the urological surgeries.

The investigators study in the similar patients, give the same intervention except the baricity of levobupivacaine. The investigators record the level of sensory block and modified Bromage score for motor blockade.

Eligibility Criteria:
Inclusion Criteria:

* ASA I-III, aged 18-70 yr, scheduled for elective gynaecologic surgery, (total abdominal hysterectomy (TAH), TAH with uni-/bilateral salpingo-oophorectomy (SO), uni-/bilateral ovarian cystectomy, or myomectomy

Exclusion Criteria:

* contraindications for spinal block, body mass index (BMI) more than 35 kg/m2 and height less than 150 cm
Evaluation of the German Short-Form Qualiveen Questionnaire

Two questionnaires (Qualiveen full version and Qualiveen short-form (SF)), the project information and the consent form will be sent to individuals who are scheduled for an annual control at the urological out-patient clinic of the Swiss Paraplegic Centre and who fulfill the inclusion criteria. The patients will be asked to complete the two questionnaires and to bring the completed questionnaires and the signed consent form to the annual control at the Swiss Paraplegic Centre. Participants who have consented and completed the two questionnaires will receive the two questionnaires a second time 14 days later.

The primary objective of this project is to validate the German version of the SF Qualiveen questionnaire. The secondary objective is to evaluate the measurement properties of the German SF Qualiveen questionnaire in comparison with the full version.


Eligibility Criteria:
Inclusion Criteria:

* chronic (≥ 12 months) neurogenic lower urinary tract dysfunction due to SCI
* age ≥ 18 years

Exclusion Criteria:

* no informed consent as documented by signature
* history of concomitant neurological or psychological illness
* history of cognitive impairment
* insufficient German language skills
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

On 6 Feb 2014, Pristiq was approved for the treatment of Major Depressive Disorder(MDD) in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS for 600 patients by 5 Feb 2020. Post marketing surveillance is required to determine any problems or questions associated with Pristiq after marketing, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of pristiq will be observed.

The objective of this study is to determine any problems or questions associated with Pristiq after marketing, with regard to the following clauses under conditions of general clinical practice, in compliance with the regulation "Re-examination guideline of new drugs (Ministry of Food and Drug Safety Notification 2013-251, 2013.12.20)".

1. Serious adverse event/adverse drug reaction
2. Unexpected adverse event/adverse drug reaction that have not been reflected in the approved drug label.
3. Known adverse drug reaction
4. Non-serious adverse drug reaction
5. Other safety and effectiveness information

Eligibility Criteria:
Inclusion Criteria:

1. Adults 19 years of age or older, who have been received at least one dose of PRISTIQ® for the treatment of Major depressive disorder (MDD).
2. Patients who have been received for the first time after signed the 'data privacy statement'

Exclusion Criteria:

Patients to whom PRISTIQ® is contraindicated as per the local labeling;

1. Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any excipients in the PRISTIQ® formulation.
2. Serotonin syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with PRISTIQ® or Do not use PRISTIQ® within 14 days of stopping an MAOI intended to treat psychiatric disorders
Physical Activity, Sedentary Behaviour and Physical Fitness Profile of Primary School Children in Lagos, Nigeria.

This research study intends to use a mixed method approach(both qualitative and quantitative) to describe and analyse the levels, patterns, and correlates of physical activity((PA), sedentary behaviour(SB), and physical fitness(PF) profiles of primary school children in Lagos state, Nigeria. The study is in four phases.

Phase1 is a scoping review of literature of the level of compliance of all the countries in sub-saharan Africa to the Global observatory on physical activity(GOPA) recommendation on the minimum level of daily physical activity to reduce incidence of non communicable chronic diseases e.g. hypertension, diabetes, obesity etc.

Phase2 is a concurrent mixed method which will explore parents and other stakeholders awareness, understanding and perspectives on PA,SB, and PF among primary school children in Lagos, Nigeria.

Phase 3 is a cross sectional study which will investigate levels, patterns and correlates among physical activity, sedentary behaviour and physical fitness profile of primary school children in Lagos, Nigeria.

Phase 4 is development of physical activity guideline for primary school children in Lagos, Nigeria.

Eligibility Criteria:
Inclusion Criteria: 1.Must be Primary school children between ages 6 and 12 years in Lagos, Nigeria.

-

Exclusion Criteria:

1. Obvious lower limb musculoskeletal diseases.
2. Normal gait impairment.
Examining the Influence of Guided Meditation on Diabetes-related Distress and Glycemic Control

The study aims to investigate the effects of Guided Meditation on diabetes-related distress and glycemic control in hospitalized Type 1 adolescent diabetic patients. The study will employ a randomized controlled trial design, with participants randomly assigned to either the intervention group (receiving Guided Meditation sessions) or the control group (receiving standard care). The primary outcomes measured will be diabetes-related distress levels and glycemic control (HbA1c levels).

The researchers hypothesize that the intervention group will experience a reduction in diabetes-related distress and an improvement in glycemic control compared to the control group. The study's findings could suggest how guided meditation could help manage the emotional distress and enhance diabetes management in hospitalized Type 1 adolescent diabetic patients.

Eligibility Criteria:
Inclusion Criteria:

* Adolescent patients aged between 12 to 18 years.
* Confirmed diagnosis of Type 1 diabetes mellitus.
* Hospitalized in the participating medical facility.
* Capable of providing informed consent (for participants aged 18) or providing assent with parental/legal guardian consent (for participants aged 12 to 17).

Exclusion Criteria:

* Presence of severe psychiatric disorders or cognitive impairments that may hinder participation in the guided meditation sessions.
* Physical limitations or medical conditions that prevent the safe participation in the intervention or assessment procedures.
* Previously engaged in regular meditation or mindfulness practices, which may confound the results.
* Inability to communicate effectively in the language used for assessments and interventions.
Data Therapy Collection to Evaluate Performances of an Automated Insulin Titration Algorithm Compared to Standard Method of Titration

A data collection of blood glucose values, insulin, meal composition will be performed for a period of two months, to evaluate the performances of an automated insulin titration algorithm


Eligibility Criteria:
Inclusion criteria:

* Person with Type 1 diabetes
* Treated by basal-bolus therapy with MDI or pump
* Patient with social security or beneficiary of medical coverage
* Patient using functional insulin therapy or starting and education course
* Patient able to read and understand the procedure, and able to express consent for study protocol

Exclusion criteria:

* Patient abusing substances
* Patient deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, patient having a psychological condition making him unable to follow and understand study protocol
A Cluster-randomized Trial to Assess a Sexual Assault Prevention Intervention in Adolescents in Nairobi, Kenya

The primary objective of this study is to compare the effectiveness of classroom-based behavioral interventions (12-hour girls program and 12-hour boys program), to a standard-of care intervention, on reducing the incidence of self-reported sexual assault among girls from baseline.

Secondary objectives of this study is to determine the impact of the interventions on related physical and mental health status/outcomes, STI-risk behaviors, self-efficacy, and self-esteem.

In Kenya, up to 46% of women report childhood sexual assault. In an implementation research project, a team at Stanford University will be pairing with three Kenyan NGO's to research the effectiveness of an intervention to prevent sexual assault among adolescent girls in the informal settlements around Nairobi, Kenya. The study design will be a cluster-randomized controlled trial with two arms comparing the intervention to a standard of care group. The intervention consists of two side-by-side behavioral and skills-based interventions, one for girls and one for boys, taught in schools. The interventions include identifying and avoiding risky situations, verbal techniques to diffuse situations, as well as bystander intervention techniques for boys and self-defense techniques for girls. Settlements with schools participating in the project include Kibera, Dandora, Huruma, and Mukuru.

This grant is part of the larger "What Works to Prevent Violence: A global program to prevent violence against women and girls" initiative, which is a large international initiative aimed at the prevention of gender-based violence. The initiative includes 18 projects from around the globe, and is supported by the Medical Research Council of South Africa, the London School of Hygiene and Tropical Medicine, and the UK Department for International Development (DFID). The primary contact people at Stanford University for this project are Clea Sarnquist, DrPH, MPH (cleas@stanford.edu) and Michael Baiocchi, PhD (baiocchi@stanford.edu).

Eligibility Criteria:
Inclusion Criteria:

* Adolescents aged 11-15 years
* Enrolled in the target schools
* Able to communicate in the study languages: English or Kiswahili

Exclusion Criteria:

* significant mental condition (learning difficulty, mental illness or substance abuse) which would impair their ability to consent to participation in the trial.